North Star Asset Management Inc. decreased its position in Haemonetics Corporation (NYSE:HAE) by 31.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,960 shares of the medical instruments supplier’s stock after selling 10,685 shares during the quarter. North Star Asset Management Inc.’s holdings in Haemonetics Corporation were worth $907,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of HAE. Shine Investment Advisory Services Inc. acquired a new stake in Haemonetics Corporation in the second quarter valued at approximately $132,000. Riverhead Capital Management LLC grew its position in Haemonetics Corporation by 79.3% in the second quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock valued at $135,000 after acquiring an additional 1,507 shares in the last quarter. Pacad Investment Ltd. acquired a new stake in Haemonetics Corporation in the second quarter valued at approximately $174,000. Ameritas Investment Partners Inc. acquired a new stake in Haemonetics Corporation in the first quarter valued at approximately $179,000. Finally, Shelton Capital Management acquired a new stake in Haemonetics Corporation in the second quarter valued at approximately $204,000.

HAE has been the subject of several recent research reports. BidaskClub downgraded shares of Haemonetics Corporation from a “hold” rating to a “sell” rating in a research report on Friday, June 23rd. Morgan Stanley reiterated an “equal weight” rating and set a $43.00 target price (up from $38.00) on shares of Haemonetics Corporation in a research note on Friday, October 6th. Barrington Research upgraded Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 target price for the company in a research note on Tuesday, August 8th. Zacks Investment Research upgraded Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Thursday, August 24th. Finally, TheStreet upgraded Haemonetics Corporation from a “c” rating to a “b-” rating in a research note on Monday, August 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $44.83.

WARNING: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.watchlistnews.com/north-star-asset-management-inc-sells-10685-shares-of-haemonetics-corporation-hae/1632807.html.

Shares of Haemonetics Corporation (NYSE HAE) traded down 0.93% during trading on Friday, reaching $45.62. The company had a trading volume of 426,247 shares. Haemonetics Corporation has a 12 month low of $32.76 and a 12 month high of $46.85. The firm has a market capitalization of $2.40 billion, a PE ratio of 592.47 and a beta of 0.87. The stock has a 50 day moving average price of $43.70 and a 200 day moving average price of $41.63.

Haemonetics Corporation (NYSE:HAE) last announced its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The company had revenue of $211.00 million for the quarter, compared to analyst estimates of $211.29 million. During the same quarter last year, the firm earned $0.25 EPS. Haemonetics Corporation’s revenue for the quarter was up .5% compared to the same quarter last year. On average, equities research analysts forecast that Haemonetics Corporation will post $1.61 EPS for the current year.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.